EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

Area of Science:

• Oncology
• Molecular Imaging
• Radiotherapy

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is aggressive and therapy-resistant, necessitating novel treatment strategies.
• Current treatments for PDAC offer limited improvements in patient outcomes.
• There is an urgent need for innovative radiotheranostic approaches for PDAC.

Purpose of the Study:

• To investigate EphA2 as a potential molecular target for PDAC radiotheranostics.
• To develop and evaluate EphA2-targeted agents for both diagnostic imaging and therapeutic intervention in PDAC.

Main Methods:

• Genomic data analysis (CCLE, TCGA) and immunohistochemistry confirmed elevated EphA2 expression in PDAC.
• Development of a gallium-68 labeled peptide for PET imaging of EphA2-expressing cells.
• Development of an actinium-225 labeled peptide for targeted alpha-particle radiotherapy.

Main Results:

• Gallium-68 labeled peptide demonstrated specific binding and internalization in EphA2-positive PDAC cells.
• In vivo PET imaging confirmed high tumor uptake and minimal off-target accumulation.
• Actinium-225 labeled peptide showed dose-dependent cytotoxicity and significant tumor growth inhibition in preclinical models with manageable toxicity.

Conclusions:

• EphA2 is a viable target for developing novel radiotheranostic agents for PDAC.
• EphA2-targeted imaging and therapy show significant potential for personalized PDAC treatment.
• Further optimization of EphA2-targeted agents is warranted to improve outcomes for PDAC patients.